Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amniogen is a human amniotic suspension allograft (ASA) being evaluated for the treatment of symptomatic knee osteoarthritis. It is a biologic product derived from human amniotic membrane and potentially human amniotic fluid-derived cells, which contain a rich milieu of growth factors and cytokines. Administered via intra-articular injection, Amniogen is designed to provide functional improvement and symptomatic relief by leveraging its anti-inflammatory and chondroregenerative properties. Its mechanism of action involves the modulation of inflammatory cytokines and the promotion of M2 macrophage polarization, which helps to reduce joint inflammation and facilitate tissue repair. The product is currently being studied in a prospective, double-blind, randomized controlled trial at Kaohsiung Veterans General Hospital in comparison to platelet-rich plasma (PRP) and hyaluronic acid (HA).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amniogen (Kaohsiung Veterans General Hospital).